BY Ron Gillmore

Cetuximab, marketed as Erbitux®å, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients, shortening overall survival.

A study at The University of Texas MD Anderson Cancer Center may help explain why the body sometimes becomes resistant to this therapy. The results, published recently in the Journal of Clinical Investigation, reveal new insight into how key proteins, known as...